Skip links

What is Semaglutide: Explore the Benefits & Side Effects

As the prevalence of type-2 diabetes continues to rise, there is an urgent need for effective treatment strategies. Now the focus is on long-term safety aspects to combat this debilitating disease. All these efforts have prompted clinicians to examine glucagon-like peptide-1 receptor agonists closely. It’s a newer class of antihyperglycemic drugs derived from the gut hormone GLP-1. And one of the GLP-1RA that has immense therapeutic potential is Semaglutide!

So what is Semaglutide? What are the benefits and potential side effects of this drug?

In this article, we explore all these questions. We’ll also tell you how to buy Semaglutide online for research purposes. So that you can contribute to the development of this wonder drug.

Let’s get started!

Part 1. What is Semaglutide?

Semaglutide is the most recently approved GLP-1 receptor agonist (GLP-1RA). It is available in both subcutaneous and oral formulations. Extensive phase 3 clinical trials have been conducted to ensure the safety profile of Semaglutide. For example, cardiovascular outcome trials have addressed potential safety concerns associated with Semaglutide.

Semaglutide has shown efficacy in improving glycemic control and inducing weight loss. So this makes it a promising treatment option for individuals with type 2 diabetes. Ongoing investigations continue to evaluate the specific effects and long-term safety of Semaglutide. In the future, it will further contribute to our understanding of its therapeutic potential. (Smits et al. 2021)

You can legally buy Semaglutide from NuScience Peptides here!

Now let’s deploy and explore the possible benefits of Semaglutide that studies have shown.

Part 2. Benefits of Semaglutide

Semaglutide offers a range of benefits in treating obesity, overweight individuals, and the glycemic control of type 2 diabetics. And the effectiveness of Semaglutide in these two areas has been extensively studied.

Let’s delve into the details of these remarkable benefits.

1.   Treatment of Obesity & Overweight

Semaglutide offers significant benefits for the treatment of obesity and overweight individuals. Obesity is a chronic disease associated with various complications and a significant burden on morbidity, mortality, and healthcare resources. Pharmacological treatments like Semaglutide serve as valuable adjuncts to lifestyle interventions, addressing the challenge of limited and difficult-to-maintain weight loss.

Remarkable Weight Loss and Improved Cardiometabolic Factors

The Semaglutide Treatment Effect in People with Obesity (STEP) clinical trial program is evaluated with once-weekly subcutaneous Semaglutide 2.4 mg. These trials were performed on individuals with overweight or obesity. Results from STEP trials show remarkable weight loss outcomes.

  • The mean weight losses range from 9% to 17.4% in participants without type 2 diabetes.
  • Significant proportions also achieved ≥10% (69%-79%) and ≥15% (51%-64%) weight
  • Cardiometabolic risk factors, physical function, and quality of life improvements were
  • Semaglutide’s safety profile remained The most prominent were gastrointestinal adverse events.

These findings hold the potential for clinically meaningful improvements in obesity-related diseases. This can offer hope for improved outcomes in this population. (Bergmann et al. 2022)

Improved Cardiometabolic Factors with Once-Weekly Semaglutide Treatment

A study was performed on overweight or obese adults with once-weekly Semaglutide treatment. It showed a significant & sustained reduction in body weight.

  • Compared to the placebo group, Semaglutide participants achieved a mean body weight reduction of -14.9% versus -2.4% at week
  • Additionally, Semaglutide users had higher percentages of weight These were 5% or more (86.4% vs. 31.5%), 10% or more (69.1% vs. 12.0%), and 15% or more (50.5% vs. 4.9%) at week 68.
  • Participants also experienced improvements in cardiometabolic risk
  • Participants reported increased physical
  • Mild-to-moderate, transient adverse events of nausea and diarrhea were
  • But the overall safety profile was (Wilding et al. 2021)You can legally buy Semaglutide from NuScience Peptides here!

Cardiovascular Outcomes by Semaglutide

2.   Glycemic Control of Type 2 Diabetics

The effect of Semaglutide on glycemic control in individuals with type 2 diabetes has also been studied extensively. In a trial comparing Oral Semaglutide, Subcutaneous Semaglutide, and placebo;

  • Significant reductions in HbA1c levels were The results occurred with both oral Semaglutide (dosage-dependent range: -0.7% to -1.9%) and subcutaneous Semaglutide (-1.9%) compared to placebo (-0.3%).
  • Reductions in body weight were also greater with oral Semaglutide (dosage-dependent range: -2.1 kg to -6.9 kg) and subcutaneous Semaglutide (-6.4 kg) compared to placebo (-1.2 kg).
  • Adverse events, primarily mild to moderate gastrointestinal events, were


These findings indicate that oral Semaglutide improves glycemic control in patients with type-2 diabetes. This is when compared to a placebo over 26 weeks. The results support further phase 3 studies to evaluate long-term clinical outcomes and safety considerations.

In short, Semaglutide shows promise as an effective treatment option for individuals with type-2 diabetes. It offers potential benefits in both glycemic control and weight management. (Davies et al. 2017)

Cardiovascular Outcomes in Type 2 Diabetics

In patients with type-2 diabetes at high cardiovascular risk, Semaglutide was studied.

  • It significantly reduced cardiovascular death rates, nonfatal myocardial infarction, and nonfatal stroke compared to
  • The SUSTAIN-6 study showed that Semaglutide was non-inferior to placebo regarding cardiovascular
  • There were lower rates of new or worsening nephropathy in the Semaglutide
  • But an increased risk of retinopathy complications was
  • Fewer serious adverse events occurred with
  • Some patients discontinued treatment due to gastrointestinal side

These findings highlight the potential cardiovascular benefits of Semaglutide in patients with type 2 diabetes at high cardiovascular risk. (Marso et al. 2016)

Cardiovascular Outcomes by Semaglutide

 You can legally buy Semaglutide from NuScience Peptides here!

Now that we’ve seen the benefits of Semaglutide, one question remains in every researcher’s mind. Is Semaglutide safe? Let’s answer it.

Part 3. Is Semaglutide Safe to Use? What are the Side Effects?

When examining the effects of GLP-1RAs, the primary on-target effects revolve around their ability to reduce glucose levels. These effects directly align with the intended therapeutic outcome.

However, any additional effects observed beyond glucose reduction can be classified as

off-target. In certain instances, these effects may manifest as unwanted actions. And these are called adverse effects.

Understanding the broader spectrum of effects is crucial in evaluating the safety profile of specific GLP-1RAs, such as Semaglutide. Here’s a result of the study examining the potential side effects of Semaglutide. (Smits et al. 2021)


GLP-1RA therapy mainly lowers blood glucose levels. But severe hypoglycemia is infrequent and often occurs when combined with sulfonylurea or insulin therapy.

Gastrointestinal (GI) Adverse Effects

Both oral and subcutaneous Semaglutide can cause gastrointestinal disturbances. The patient can feel effects such as nausea, vomiting, and diarrhea. These are common but usually mild to moderate in severity and self-limiting.

GI side effects of Semaglutide

Pancreatic Adverse Events

Studies have not shown a clear association between Semaglutide and pancreatitis or pancreatic cancer. At the same time, some data suggest an increase in pancreatic enzyme levels. The clinical significance is unclear.

Thyroid Cancer

Animal studies initially suggested a potential risk of thyroid cancer. But human studies have not shown a definitive association.

Still, Semaglutide is contraindicated in patients with a history of medullary thyroid carcinoma. Similarly, it is also contraindicated with multiple endocrine neoplasia type 2 (MEN2).


GLP-1RAs, including Semaglutide, may increase the risk of gallbladder events like gallstones. The exact mechanism is unclear. But it may involve changes in gallbladder motility or bile salts.


Semaglutide increases heart rate. But this is not associated with adverse cardiac events. Long-term cardiovascular safety beyond the duration of clinical trials has not been studied yet.

Acute Kidney Injury

Semaglutide has not been consistently associated with acute kidney injury. The risk may be increased in certain patients. For example, patients with dehydration or taking medications that affect fluid balance.

Diabetic Retinopathy

Semaglutide has been associated with a risk of diabetic retinopathy. However, the initial worsening may be due to the rapid improvement in glycemic control. And long-term effects on the retina are still being investigated.

Injection-Site and Allergic Reactions

Semaglutide has a low incidence of injection-site reactions. And allergic reactions are rare. But these possible effects may include rash, itching, or swelling.

Side Effects of Semaglutide 

Most of these side effects are mild to moderate. So Semaglutide still shows potential in type 2 diabetics.

But there is still a need for further study. If you are a researcher looking to buy Semaglutide online, the next section is for you.

Part 4. Availability and Convenience: Buy Semaglutide Online

Looking to buy it online? Look no further than NuScience Peptides, your trusted source for high-quality research peptides.

At NuScience Peptides;

  • We prioritize accurate We offer a wide range of peptides as well as SARMS at competitive prices.
  • Our commitment to purity is Every product undergoes rigorous lab testing to ensure the highest possible quality.
  • And you can enjoy the convenience of swift delivery with same-day This is applied to all in-stock items before 12:00 pm EST.
  • Our dedicated team is always ready to assist you with customer service And we always prioritize your satisfaction.
  • We offer free shipping on orders totaling $125 or more

So let us be your trusted ally in advancing scientific understanding. Buy Semaglutide online from NuScience Peptides. And join our vibrant community of researchers.

Semaglutide from NuScience Peptides


So what is Semaglutide? It’s a GLP-1 receptor agonist with significant promise as a treatment option for individuals with type 2 diabetes and obesity-related diseases.

Extensive clinical trials have demonstrated its efficacy in improving glycemic control and inducing weight loss. At the same time, some side effects have also been reported. But still, Semaglutide has shown a favorable safety profile overall.


Bergmann, N. C., Davies, M. J., Lingvay, I., & Knop, F. K. (2022). Semaglutide for the treatment of overweight and obesity: A review. Diabetes, Obesity and Metabolism, 25(1), 18–35.

Davies, M. (2017). Effect of oral Semaglutide compared with placebo and subcutaneous Semaglutide on glycemic control in patients. JAMA, 318(15), 1460–1470.

Marso. (2016, November 10). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine.

Smits, M. M., & Raalte, D. H. V. (2021). Safety of Semaglutide. Frontiers in Endocrinology, 12.

Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002.


The information provided in this blog article is for educational and informational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider regarding any medical treatment. The US Food & Drug Administration has not evaluated the statements & products mentioned in this article. They are not intended to diagnose, treat, cure, or prevent any disease. It’s all for research purposes only.